BlackRock, Inc. 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-06-09 3:20 pm Sale | 2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 117,707 4.800% | -2,233 (-1.86%) | Filing |
| 2022-06-09 3:20 pm Purchase | 2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 117,707 4.800% | 117,707 (New Position) | Filing |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 119,939 6.100% | -9,660 (-7.45%) | Filing |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 129,599 6.800% | 53,107 (+69.43%) | Filing |
| 2020-05-08 10:58 am Sale | 2020-04-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 76,492 4.300% | -396 (-0.52%) | Filing |